Drug Trial Radar · NCT06637631
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
105
Actual
Start
Dec 10, 2024
Primary completion
Jul 30, 2026
Study completion Oct 2, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD. This study will have an anticipated duration of up to 59 weeks which will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatment period, lasting 52 weeks, and a 2-week follow-up period after end of treatment for participants not enrolling in the Long Term Safety (LTS) study. The MS period includes a Double-Blind (DB) treatment period with 12 weeks of induction followed by 40 weeks of maintenance. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. The combined duration of the DB maintenance and OL periods cannot exceed 40 weeks, depending on when participants switch.
Conditions
- Crohn's Disease
Interventions
SAR441566Drug
Pharmaceutical form: Tablet Route of administration: Oral
SAR441566 matching PlaceboDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving endoscopic responseTime frame: Week 12
Locations
141 sites in 24 countries. Site status is shown where the registry gives one.
GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400020
Sun City, Arizona
Bristol Hospital- Site Number : 8400007
Bristol, Connecticut
Novum Research- Site Number : 8400021
Clermont, Florida
Homestead Associates in Research- Site Number : 8400012
Homestead, Florida
Clinical Research of Osceola- Site Number : 8400013
Kissimmee, Florida
Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400010
Miami Lakes, Florida
GCP Clinical Research- Site Number : 8400004
Tampa, Florida
GI Alliance - Glenview- Site Number : 8400015
Glenview, Illinois
Illinois Gastroenterology Group- Site Number : 8400011
Gurnee, Illinois
University of Michigan Health System - Ann Arbor- Site Number : 8400017
Ann Arbor, Michigan
Gi Alliance - Flowood- Site Number : 8400019
Flowood, Mississippi
Vector Clinical Trials- Site Number : 8400001
Las Vegas, Nevada
Queens Village Primary Medical Center- Site Number : 8400005
Queens Village, New York
Carolina Digestive Diseases and Endoscopy Center- Site Number : 8400014
Greenville, North Carolina
Frontier Clinical Research - Uniontown- Site Number : 8400009
Uniontown, Pennsylvania
Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400016
Charleston, South Carolina
Gastro Health & Nutrition- Site Number : 8400003
Katy, Texas
Texas Digestive Disease Consultants - Southlake- Site Number : 8400002
Southlake, Texas
Washington Gastroenterology - Tacoma- Site Number : 8400008
Tacoma, Washington
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320005
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320004
Buenos Aires, Argentina
Investigational Site Number : 0320006
Buenos Aires, Argentina
Investigational Site Number : 0320002
San Miguel de Tucumán, Tucumán Province, Argentina
Investigational Site Number : 0360002
Sydney, New South Wales, Australia
Investigational Site Number : 0360001
South Brisbane, Queensland, Australia
Investigational Site Number : 0360003
Parkville, Victoria, Australia
Centro de Pesquisas da Clínica IBIS- Site Number : 0760001
Salvador, Estado de Bahia, Brazil
Hospital Moinhos de Vento- Site Number : 0760006
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clinicas de Porto Alegre- Site Number : 0760007
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Ernesto Dornelles- Site Number : 0760002
Porto Alegre, Rio Grande do Sul, Brazil
Pesquisare Saude- Site Number : 0760004
Santo André, São Paulo, Brazil
Investigational Site Number : 1000001
Gorna Oryahovitsa, Bulgaria
Investigational Site Number : 1000004
Sofia, Bulgaria
Investigational Site Number : 1000005
Sofia, Bulgaria
Investigational Site Number : 1240001
Calgary, Alberta, Canada
Investigational Site Number : 1240003
Montreal, Quebec, Canada
Investigational Site Number : 1240005
Québec, Quebec, Canada
Investigational Site Number : 1520006
Concepción, Biobio, Chile
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.